These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 28267710

  • 1. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P, He Q.
    Br J Cancer; 2017 Apr 11; 116(8):1027-1036. PubMed ID: 28267710
    [Abstract] [Full Text] [Related]

  • 2. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V, De Cesare M, Zaffaroni N, Lanzi C, Cassinelli G.
    Oncotarget; 2015 Apr 20; 6(11):8736-49. PubMed ID: 25826089
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY, Luo F, Li XY, Fu XF, He JF, Tian YZ, Zhu JJ, Chu XY, Zhao HL.
    Anticancer Agents Med Chem; 2019 Apr 20; 19(6):740-749. PubMed ID: 30836927
    [Abstract] [Full Text] [Related]

  • 4. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
    Mok WC, Wasser S, Tan T, Lim SG.
    World J Gastroenterol; 2012 Jul 21; 18(27):3527-36. PubMed ID: 22826617
    [Abstract] [Full Text] [Related]

  • 5. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D, Chang R, Wang G, Hu B, Qiang Y, Chen Z.
    Anticancer Agents Med Chem; 2017 Jul 21; 17(7):948-954. PubMed ID: 27671301
    [Abstract] [Full Text] [Related]

  • 6. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C, Wang X, Fang D, Xu P, Mo X, Hu C, Abdelatty A, Wang M, Xu H, Sun Q, Zhou G, She J, Xia J, Hui KM, Xia H.
    Theranostics; 2021 Jul 21; 11(5):2108-2122. PubMed ID: 33500714
    [Abstract] [Full Text] [Related]

  • 7. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.
    Gastroenterology; 2012 Mar 21; 142(3):521-530.e3. PubMed ID: 22108192
    [Abstract] [Full Text] [Related]

  • 8. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
    Tao YF, Li ZH, Du WW, Xu LX, Ren JL, Li XL, Fang F, Xie Y, Li M, Qian GH, Li YH, Li YP, Li G, Wu Y, Feng X, Wang J, He WQ, Hu SY, Lu J, Pan J.
    Oncol Rep; 2017 Mar 21; 37(3):1419-1429. PubMed ID: 28184925
    [Abstract] [Full Text] [Related]

  • 9. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX.
    Cancer Biother Radiopharm; 2011 Aug 21; 26(4):427-36. PubMed ID: 21797676
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
    Tang Q, Hu G, Sang Y, Chen Y, Wei G, Zhu M, Chen M, Li S, Liu R, Peng Z.
    Clin Transl Med; 2024 May 21; 14(5):e1703. PubMed ID: 38769666
    [Abstract] [Full Text] [Related]

  • 11. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
    Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, Engels K, Pleli T, Benz A, Canamero M, Longerich T, Kronenberger B, Richter S, Waidmann O, Vogl TJ, Zeuzem S, Piiper A.
    Neoplasia; 2012 May 21; 14(5):410-9. PubMed ID: 22745587
    [Abstract] [Full Text] [Related]

  • 12. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
    Dai XY, Zhuang LH, Wang DD, Zhou TY, Chang LL, Gai RH, Zhu DF, Yang B, Zhu H, He QJ.
    Oncotarget; 2016 Feb 09; 7(6):6933-47. PubMed ID: 26771844
    [Abstract] [Full Text] [Related]

  • 13. Enhanced chemosensitivity to CPT-11 in colorectal carcinoma xenografts by small hairpin RNA interference targeting PLK1.
    Fan P, Zhang S, Tian H, Yan N, Dai L, Zhang X, Cheng L, Li C, Li Y, Chen X, Shi G, Yang Y, Wei Y, Deng H.
    Neoplasma; 2012 Feb 09; 59(6):676-84. PubMed ID: 22862168
    [Abstract] [Full Text] [Related]

  • 14. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.
    Deng H, Jiang Q, Yang Y, Zhang S, Ma Y, Xie G, Chen X, Qian Z, Wen Y, Li J, Yang J, Chen L, Zhao X, Wei Y.
    Cancer Biol Ther; 2011 Feb 15; 11(4):401-9. PubMed ID: 21150280
    [Abstract] [Full Text] [Related]

  • 15. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
    Cho Y, Lee YB, Lee JH, Lee DH, Cho EJ, Yu SJ, Kim YJ, Kim JI, Im JH, Lee JH, Oh EJ, Yoon JH.
    PLoS One; 2016 Feb 15; 11(8):e0160822. PubMed ID: 27494117
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
    Yunoki T, Tabuchi Y, Hayashi A, Kondo T.
    Invest Ophthalmol Vis Sci; 2013 Dec 23; 54(13):8353-63. PubMed ID: 24366665
    [Abstract] [Full Text] [Related]

  • 17. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
    Zhou J, Gao Q, Chen G, Huang X, Lu Y, Li K, Xie D, Zhuang L, Deng J, Ma D.
    Clin Cancer Res; 2005 Dec 01; 11(23):8431-40. PubMed ID: 16322306
    [Abstract] [Full Text] [Related]

  • 18. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S, Lanvers-Kaminsky C, Daudigeos-Dubus E, LE Dret L, Laplace-Builhe C, Molenaar J, Vassal G, Geoerger B, within the ITCC Biology and Preclinical Evaluation Committee.
    Anticancer Res; 2016 Feb 01; 36(2):599-609. PubMed ID: 26851014
    [Abstract] [Full Text] [Related]

  • 19. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
    Tian L, Yao K, Liu K, Han B, Dong H, Zhao W, Jiang W, Qiu F, Qu L, Wu Z, Zhou B, Zhong M, Zhao J, Qiu X, Zhong L, Guo X, Shi T, Hong X, Lu S.
    Oncogene; 2020 Apr 01; 39(15):3145-3162. PubMed ID: 32060423
    [Abstract] [Full Text] [Related]

  • 20. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C.
    J Hepatol; 2012 Jan 01; 56(1):176-83. PubMed ID: 21835141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.